Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

N Engl J Med 2003 Jul;349(3):247-57

Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Toronto.

Background: Colon cancers with high-frequency microsatellite instability have clinical and pathological features that distinguish them from microsatellite-stable tumors. We investigated the usefulness of microsatellite-instability status as a predictor of the benefit of adjuvant chemotherapy with fluorouracil in stage II and stage III colon cancer.

Methods: Tumor specimens were collected from patients with colon cancer who were enrolled in randomized trials of fluorouracil-based adjuvant chemotherapy. Microsatellite instability was assessed with the use of mononucleotide and dinucleotide markers.

Results: Of 570 tissue specimens, 95 (16.7 percent) exhibited high-frequency microsatellite instability. Among 287 patients who did not receive adjuvant therapy, those with tumors displaying high-frequency microsatellite instability had a better five-year rate of overall survival than patients with tumors exhibiting microsatellite stability or low-frequency instability (hazard ratio for death, 0.31 [95 percent confidence interval, 0.14 to 0.72]; P=0.004). Among patients who received adjuvant chemotherapy, high-frequency microsatellite instability was not correlated with increased overall survival (hazard ratio for death, 1.07 [95 percent confidence interval, 0.62 to 1.86]; P=0.80). The benefit of treatment differed significantly according to the microsatellite-instability status (P=0.01). Adjuvant chemotherapy improved overall survival among patients with microsatellite-stable tumors or tumors exhibiting low-frequency microsatellite instability, according to a multivariate analysis adjusted for stage and grade (hazard ratio for death, 0.72 [95 percent confidence interval, 0.53 to 0.99]; P=0.04). By contrast, there was no benefit of adjuvant chemotherapy in the group with high-frequency microsatellite instability.

Conclusions: Fluorouracil-based adjuvant chemotherapy benefited patients with stage II or stage III colon cancer with microsatellite-stable tumors or tumors exhibiting low-frequency microsatellite instability but not those with tumors exhibiting high-frequency microsatellite instability.

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa022289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584639PMC
July 2003
12 Reads

Publication Analysis

Top Keywords

microsatellite instability
32
adjuvant chemotherapy
28
high-frequency microsatellite
24
tumors exhibiting
16
confidence interval
12
colon cancer
12
hazard ratio
12
fluorouracil-based adjuvant
12
ratio death
12
microsatellite-instability status
12
percent confidence
12
[95 percent
12
microsatellite-stable tumors
12
microsatellite
10
instability
9
benefit adjuvant
8
tumors
8
stage stage
8
survival patients
8
tumors tumors
8

Similar Publications